Niklas Karlsson1, Mark J Atkinson2, Hana Müllerová3, Marianna Alacqua3, Christina Keen4, Rod Hughes3, Christer Janson5, Barry Make6, David Price7,8, Helen K Reddel9. 1. BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. 2. Evidera, Bethesda, MD, USA. 3. BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. 4. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. 5. Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden. 6. National Jewish Health and University of Colorado Denver, Denver, CO, USA. 7. Observational and Pragmatic Research Institute, Singapore, Singapore. 8. Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 9. Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.
Abstract
Background: The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD). Methods: Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study (ClinicalTrials.gov: NCT02760329). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses. Results: For the total sample, the mean±sd RSQ score was 5.6±4.3 (range 0-16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76-0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of -2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7-2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p<0.001). Conclusions: The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.
Background: The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD). Methods: Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study (ClinicalTrials.gov: NCT02760329). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses. Results: For the total sample, the mean±sd RSQ score was 5.6±4.3 (range 0-16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76-0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of -2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7-2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p<0.001). Conclusions: The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.
Authors: M Cazzola; W MacNee; F J Martinez; K F Rabe; L G Franciosi; P J Barnes; V Brusasco; P S Burge; P M A Calverley; B R Celli; P W Jones; D A Mahler; B Make; M Miravitlles; C P Page; P Palange; D Parr; M Pistolesi; S I Rennard; M P Rutten-van Mölken; R Stockley; S D Sullivan; J A Wedzicha; E F Wouters Journal: Eur Respir J Date: 2008-02 Impact factor: 16.671
Authors: Michelle M Cloutier; Michael Schatz; Mario Castro; Noreen Clark; H William Kelly; Rita Mangione-Smith; James Sheller; Christine Sorkness; Stuart Stoloff; Peter Gergen Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Sandra R Wilson; Cynthia S Rand; Michael D Cabana; Michael B Foggs; Jill S Halterman; Lynn Olson; William M Vollmer; Rosalind J Wright; Virginia Taggart Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Adam Gater; Linda Nelsen; Sarah Fleming; J Jason Lundy; Nicola Bonner; Rebecca Hall; Chris Marshall; Hannah Staunton; Jerry A Krishnan; Stuart Stoloff; Michael Schatz; John Haughney Journal: Value Health Date: 2016-03-30 Impact factor: 5.725
Authors: Nancy K Leidy; Lindsey T Murray; Brigitta U Monz; Linda Nelsen; Mitchell Goldman; Paul W Jones; Elizabeth J Dansie; Sanjay Sethi Journal: Respir Res Date: 2014-10-07
Authors: Helen K Reddel; Maria Gerhardsson de Verdier; Alvar Agustí; Gary Anderson; Richard Beasley; Elisabeth H Bel; Christer Janson; Barry Make; Richard J Martin; Ian Pavord; David Price; Christina Keen; Asparuh Gardev; Stephen Rennard; Alecka Sveréus; Aruna T Bansal; Lance Brannman; Niklas Karlsson; Javier Nuevo; Fredrik Nyberg; Simon S Young; Jørgen Vestbo Journal: ERJ Open Res Date: 2019-02-01